restricting the use of Tasmar (tolcapone) due to reports of serious hepatotoxicity
The FDA recommends restricting the use of Tasmar (tolcapone) due to reports of serious hepatotoxicity...including three deaths.
Tasmar came out earlier this year. It's used to prolong the effect of levodopa in patients with advanced Parkinson's.
Now the FDA recommends limiting Tasmar to patients who can't take or don't respond to other Parkinson's drugs.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote